Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Landau

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A Gertz, Heather Landau, Raymond L Comenzo, et al.
Blood Advances|February 24, 2023
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawalMark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, et al.
Leukemia & Lymphoma|January 13, 2017
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantationGunjan L Shah, Heather Landau, Dory Londono, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Leukemia & Lymphoma|May 10, 2017
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenanceHani Hassoun, Mikhail Roshal, Joshua Sabari, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 18, 2023
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain AmyloidosisMorie Gertz, Rafat Abonour, Sarah N Gibbs, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2019
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body <sup>18</sup>F-Florbetapir PET/CTEric C Ehman, M Samir El-Sady, Marie F Kijewski, et al.
Journal of Onco-Nephrology|February 18, 2026
Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United StatesSamhita Boppana, Christopher D Blosser, Allison B Webber, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A Gertz, Heather Landau, Raymond L Comenzo, et al.
Blood Advances|February 24, 2023
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawalMark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, et al.
Leukemia & Lymphoma|January 13, 2017
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantationGunjan L Shah, Heather Landau, Dory Londono, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Leukemia & Lymphoma|May 10, 2017
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenanceHani Hassoun, Mikhail Roshal, Joshua Sabari, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 18, 2023
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain AmyloidosisMorie Gertz, Rafat Abonour, Sarah N Gibbs, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2019
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body <sup>18</sup>F-Florbetapir PET/CTEric C Ehman, M Samir El-Sady, Marie F Kijewski, et al.
Journal of Onco-Nephrology|February 18, 2026
Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United StatesSamhita Boppana, Christopher D Blosser, Allison B Webber, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Pageof 10